GlaxoSmithKline poaches Pfizer's viral vaccines lead in rush to capitalize on future of mRNA
GlaxoSmithKline has appointed Philip Dormitzer, formerly chief scientific officer of Pfizer’s viral vaccines unit, as its newest global head of vaccines R&D, looking to leverage one of the leading minds behind Pfizer and BioNTech’s RNA collaboration that led to Covid-19 jab Comirnaty, the British drug giant said Tuesday.
Dormitzer had been with Pfizer for a little more than six years, joining up after a seven-year stint with Novartis, where he reached the role of US head of research and head of global virology for the company’s vaccines and diagnostics unit.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.